Overall, they are indicative of potential efficacy. In palmoplantar psoriasis, ustekinumab therapy was well tolerated without any reported adverse effects. Ustekinumab has been shown in small studies to be useful in other forms of psoriasis, including nail psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. The safety and efficacy of ustekinumab for adult moderate to severe plaque Ps was confirmed in two phase III, multicenter, randomized, double-blind, placebo-controlled trials, PHOENIX 1 and PHOENIX 2 (Leonardi, 2008; Papp, 2008). Gov database identified several phase I-III trials evaluating the use of ustekinumab in combination therapy for the prevention of acute graft-versus-host disease (GVHD) and as a single agent for AS (Poddubnyy, 2014), hidradenitis suppurativa, primary biliary cirrhosis, psoriasis vulgaris, RA, and severe palmar plantar psoriasis.
Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial. Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab. Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis. One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and soles after 16 Weeks of treatment with Cosentyx; severity of nail psoriasis decreased by almost a half 1, 2. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
In fact, the efficacy of various biologic therapies in psoriasis has been shown in numerous clinical studies, and, importantly, associated with an improved quality of life for the patients 10, 11. In addition, a recent open-label trial evaluating the efficacy of ustekinumab in palmoplantar psoriasis provided evidence that the higher dosing of 90 mg may have utility in treating this psoriasis variant that is known to be resistant to many other forms of treatment 47. Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life. We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis. Palmoplantar psoriasis and palmoplantar pustulosis are chronic skin diseases with a large impact on patient quality of life. They are frequently refractory to treatment, being generally described as a therapeutic challenge.
Safety And Efficacy Of Ustekinumab In Adolescent Patients With Moderate To Severe Plaque Psoriasis: Results Through 1 Year Of The Phase 3 Cadmus Trial